Search
for
Sort by
Research 421–450 of 1000+
- Baricitinib for the Treatment of Alopecia Areata
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- Topical use of calcipotriol does not potentiate squaric acid dibutylester effectiveness in the treatment of alopecia areata
- Economic Impact of Home-Use versus Office-Use Diphenylcyclopropenone in Extensive Alopecia Areata
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
- Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
- Retrospective Study about the Effectiveness of Korean Medical Treatment on 222 Patients with Alopecia Areata
- Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Correlation between serum brain-derived neurotrophic factor level and depression severity in alopecia areata patients
- 455 Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata
- Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- P146 A multicentre retrospective study evaluating the real-world efficacy and safety of ritlecitinib in the treatment of alopecia areata
- Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Timing of Initial Hair Regrowth and Clinical Trial-Defined Response Following Ritlecitinib Treatment in Patients With Alopecia Areata
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
- Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
- Features of sensitization in patients with alopecia areata, associated with atopic diseases
- Autoinmune Alopecia/Alopecia Areata
- Baricitinib for alopecia areata